NCT02786160已完成不适用
The Effects of Human Milk Oligosaccharides (HMO) on the Faecal Microbiota and on Host Metabolism in Obese Children: A Parallel, Double-blind, Randomized, Placebo-controlled Study
Glycom A/S2 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2016年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 2
- 主要终点
- Change from baseline in faecal microbiota profile
研究概览
简要总结
The study is a randomised, placebo-controlled, double-blind, parallel study in obese children. A total of 75 obese children in the age 5 to 10 years, enrolled in a childhood obesity treatment program, will be included. The participating children will be randomised into one of three groups consuming either HMO (two groups) or placebo (one group).
The primary objective of the study is to establish the effects of HMOs on the faecal microbiota in children. Secondary objectives are to evaluate safety of HMO supplementation in children and the effect on gastrointestinal symptoms (tolerance), bowel habits, metabolic profile and body composition in obese children.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 5 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed, written consent by the child's representative(s) and informed verbal assent by the child
- •Age ≥5 and <11 years at visit 0
- •BMI SDS of ≥ 2.3
- •Enrolment in the childhood obesity treatment program at the Children's Obesity Clinic
- •Ability and willingness to understand and comply with the study procedures
- •The child's representative(s) need(s) to read, speak and understand Danish
排除标准
- •Participation in another clinical intervention study one month prior to the screening visit and throughout the study.
- •Any gastrointestinal disease(s) that may cause symptoms or may interfere with the trial outcome, as judged by the investigator.
- •Other severe disease(s) such as malignancy, kidney disease or neurological disease, as judged by the investigator.
- •Psychiatric disease, as judged by the investigator.
- •Use of probiotic supplements (yoghurt allowed) 3 months prior to screening and throughout the study.
- •Consumption of antibiotic drugs 3 months prior to screening and throughout the study.
- •Consumption on a regular basis of medication that might interfere with symptom evaluation (as judged by the investigator) 2 weeks prior to screening and throughout the study.
- •Lack of suitability for participation in the study for any reason as judged by the investigator.
结局指标
主要结局
Change from baseline in faecal microbiota profile
时间窗: Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out
次要结局
- Change from baseline in gastrointestinal symptoms measured via the gastrointestinal symptom rating scale (GSRS)(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline in haematology(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline of specific faecal biomarkers related to inflammation(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline in clinical chemistry(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline in Bristol Stool Form Scale (BSFS)(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline of hip circumference(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline of fat percentage(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline in specific host-bacteria metabolic biomarkers in blood(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline of BMI-SDS(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline of waist circumference(Baseline and after 4 and 8 weeks of intake, and after 2 and 10 months of wash-out)
- Change from baseline of specific blood biomarkers related to inflammation(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline of HOMA-IR(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
- Change from baseline of specific blood biomarkers related to gut barrier function(Baseline and after 8 weeks of intake, and after 10 months of wash-out)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy VolunteersGut MicrobiotaGastrointestinal SymptomsNCT01927900Glycom A/S100
招募中
不适用
HMOs on Infant Gut Microbiota Modulation and Development of the Immune System in Healthy InfantsHealthy InfantsNCT06631937University of Aarhus334
已完成
2 期
Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS PatientsIrritable Bowel Syndrome (IBS)NCT02875847Glycom A/S60
进行中（未招募）
不适用
Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune FunctionHealthyGastrointestinal DiseasesNCT06094153Kyowa Hakko Bio Co., Ltd.108
已完成
不适用
Effects of Human Milk Oligosaccharide Ingestion on Weight Loss and Markers of HealthWeight LossNCT06547801Advanced Protein Technologies Corporation60